

### Amendments to the claims

The listing of claims will replace all prior versions, and listings, of claims in the application.

### Listing of Claims

Claims 1-21. (Previously Canceled)

22. (Currently Amended) A method of treating or preventing restless leg syndrome which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, clathrate, or ~~prodrug~~ prodrug thereof.

23. (Original) The method of claim 22 wherein the sibutramine metabolite is optically pure.

24. (Original) The method of claim 23 wherein the sibutramine metabolite is (R)-desmethylsibutramine, (S)-desmethylsibutramine, (R)-didesmethylsibutramine, or (S)-didesmethylsibutramine.

25. (Original) The method of claim 22 which further comprises the administration of pergolide, carbidopa, levodopa, oxycodone, carbamazepine, or gabapentin, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, prodrug, optically and pharmacologically active stereoisomer, or pharmacologically active metabolite thereof.

Claims 26-40. (Canceled)

41. (Previously Added) The method of claim 22, wherein the amount of sibutramine metabolite administered is from about 0.1 mg to about 60 mg/day.

42. (Previously Added) The method of claim 41, wherein the amount of sibutramine metabolite administered is from about 2 mg to about 30 mg/day.

43. (Previously Added) The method of claim 42, wherein the amount of sibutramine metabolite administered is from about 5 mg to 15 mg/day.

44. (Previously Added) The method of claim 22, wherein the sibutramine metabolite is administered orally, mucosally, rectally, parenterally, transdermally or subcutaneously.

45. (Previously Added) The method of claim 44, wherein the sibutramine metabolite is administered orally, mucosally or transdermally.

46. (New) The method of claim 24, wherein the sibutramine metabolite is (R)-desmethylsibutramine or (R)-didesmethylsibutramine.

47. (New) The method of claim 46, wherein the sibutramine metabolite is (R)-didesmethylsibutramine.

48. (New) The method of claim 24, wherein the sibutramine metabolite is (S)-desmethylsibutramine or (S)-didesmethylsibutramine.

49. (New) The method of claim 48, wherein the sibutramine metabolite is (S)-didesmethylsibutramine.

50. (New) A method of treating or preventing restless leg syndrome which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (R)-didesmethylsibutramine, or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof.

52. (New) A method of treating or preventing restless leg syndrome which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (S)-didesmethylsibutramine, or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof.